These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 606411)

  • 1. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease.
    Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinal calcium changes with 1alpha-hydroxyvitamin D3.
    Dabek JT; Robinson BH; Naik RB; Al-Hiti K
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():147s-150s. PubMed ID: 606412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
    Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone disease in children with chronic renal failure: therapy with 1alpha-hydroxyvitamin D3.
    Postlethwaite RJ; Houston IB
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():117s-124s. PubMed ID: 304772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Junor BJ; Catto GR; Macleod M
    Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
    Pierides AM; Kerr DN; Ellis HA; Peart KM; O'Riordan JL; DeLuca HF
    Clin Nephrol; 1976 Apr; 3(2):189-96. PubMed ID: 819195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of dialysate calcium concentration on 1alpha-hydroxyvitamin D3 on skeletal calcium loss and hyperparathyroidism in haemodialysis patients.
    Winney RJ; Tothill P; Robson JS; Abbot SR; Lidgard GP; Cameron EH; Smith MA; Macpherson HN; Strong JA
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():151s-158s. PubMed ID: 606413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 13. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
    Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
    Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term therapy of uremic osteodystrophy in adults with calcitriol.
    Moorthy AV; Harrington AR; Mazess RB; Simpson DP
    Clin Nephrol; 1981 Aug; 16(2):93-100. PubMed ID: 6894893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ; Bone JM; Anderson TJ; Robson JS
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract]   [Full Text] [Related]  

  • 17. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
    Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE
    Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
    Kanis JA; Henderson RG; Heynen G; Ledingham JG; Russell RG; Smith R; Walton RJ
    Arch Dis Child; 1977 Jun; 52(6):473-81. PubMed ID: 879833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 20. 1alpha-hydroxychloecalciferol treatment of long-term hemodialyzed patients. Effects on mineral metabolism, bone mineral content and bone morphometry.
    Nielsen HE; Melsen F; Christensen MS; Hansen HE; Rodbro P; Johannsen A
    Clin Nephrol; 1977 Oct; 8(4):429-34. PubMed ID: 923161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.